Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$6.85 USD
+0.44 (6.86%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.86 +0.01 (0.15%) 6:22 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Mesoblast Limited [MESO]
Reports for Purchase
Showing records 61 - 80 ( 91 total )
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Encouraging Update on Revascor for End-Stage HF; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Eventful 2020 With Potential U.S. Approval for Ryoncil; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
We Expect a Speedy Approval for Ryoncil; Higher $14 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Stay Tuned for Data, Tweaking Our PT from $14 to $15
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Remestemcel-L BLA Nears Completion; Revascor Readout in 1H20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and $14.00 targe
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Remestemcel-L BLA Expected by YE; Eventful CY2020 Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Grunenthal Agreement Brings Capital and Validation; Higher $8.00PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Regulatory Pathway for Revascor in End-Stage HF Defined; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Remestemcel-L BLA Submission Initiated; Revascor to Report in 1H20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
FDA Gives Green Light for Remestemcel-L BLA Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Mesoblast Limited
Industry: Medical - Biomedical and Genetics
Revascor and Remestemcel-L Programs on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S